Sep 25, 2019
Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
Sep 04, 2019
Sysmex Inostics Publishes First Feasibility Study of NGS-based Liquid Biopsy to Complement Early Breast Cancer Screening by Imaging
Aug 22, 2019
High Sensitivity of Biocept's Target Selector(TM) Platform Using CEE-Sure(TM) Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
Aug 02, 2019
Sysmex Obtains Japanese Manufacturing and Marketing Approval for the First Blood-based RAS Mutation Testing for Colorectal Cancer
Jul 18, 2019
Liquid Biopsy Performance Comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS Testing Published in Scientific Reports (Nature Journal)
Jun 18, 2019
Biocept Announces Commercial Launch of Target Selector(TM) NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
Jun 03, 2019
Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma
Jun 03, 2019
Clinical Genomics Announces Poster Presentation At the 2019 ASCO Annual Meeting
Jun 03, 2019
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
May 31, 2019
Double-Digit Growth and Increased Acceptance For Liquid Biopsy: New Report
May 30, 2019
Sysmex Inostics OncoBEAM(TM)-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study
May 28, 2019
Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
May 28, 2019
Sysmex Inostics' SafeSEQ ER+/HER2- Breast Cancer Panel Demonstrates Equivalent Sensitivity to OncoBEAM(TM) Enhanced Digital PCR Technology for Detection of Mutations in Circulating Tumor DNA
May 16, 2019
Blood Test Can Measure Effectiveness of Treatments for Aggressive Skin Cancers
May 09, 2019
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
May 07, 2019
Signatera(TM) Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards
Apr 26, 2019
The Liquid Biopsy Market in Latin America, 2019 to 2025 - Products Based on Circulating Tumor Cells (CTCs) is Anticipated to Witness the Highest CAGR of 11.75% during 2018-2025
Apr 16, 2019
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
Apr 10, 2019
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma
Mar 28, 2019
ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients